Ortho Clinical Diagnostics’ Total Antibody Test Receives the US FDA’s Emergency Use Authorization for COVID-19

 Ortho Clinical Diagnostics’ Total Antibody Test Receives the US FDA’s Emergency Use Authorization for COVID-19

Ortho Clinical Diagnostics Receives the US FDA’s Emergency Use Authorization for its Total Antibody Test for COVID-19

Shots:

  • The US FDA has granted EUA to Ortho’s total Ab assay for COVID-19, the VITROS immunodiagnostic products Anti-SARS-CoV-2 total reagent pack and calibrators and is considered as one of the first high-throughput, automated COVID-19 Ab tests to be granted EUA
  • The test can be run on Orthos’ VITROS XT 7600 Integrated System, the VITROS 3600 Immunodiagnostic System, the VITROS 5600 Integrated System and will soon be available on VITROS ECi/ECiQ Immunodiagnostic System
  • The VITROS Anti-SARS-CoV-2 Ab tests are designed to be performed by laboratory professionals and cannot be directly used by patients. The test screens plasma donations for convalescent plasma therapy and when combined with molecular test, it monitors disease progression by measuring Ab appearance in the blood

Click here ­to­ read full press release/ article | Ref: Ortho Clinic Diagnostic | Image:  Ortho Clinic Diagnostic

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post